Pipeline
Rare Disease
ColiFin®
For Cystic Fibrosis Infections
Global ex-Europe rights (in-licensed from PARI Pharma GmbH)
Inhaled Murepavadin
For Cystic Fibrosis Infections
Funding by IMI and CF Foundation
EBX-002: Potentiated Inhaled Amikacin
For Non-tuberculous mycobacteria (NTM)
Lonodelestat (POL6014)
For Treatment of Cystic Fibrosis (Elastase Inhibitor)
Out-licensed to Santhera
Oncology
Balixafortide
Oncology / Non Oncology Orphan Indications
Readiness if initiated (under evaluation)
POL New CXCR4
Orphan Hematological Malignancies